Thrombelastography Based Dosing of Enoxaparin

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many times enoxaparin (or Lovenox®) is given to patients who are at a higher risk of developing clots in their legs or lungs. Recent data suggest that a standard dose of Lovenox may not fully prevent the development of these clots especially in critically ill or obese patients. Routine enoxaparin dosing can also result in bleeding complications. Thrombelastography (TEG®) can be used to measure how blood clots. The purposes of this study are:

• to learn if the TEG® can better guide physicians in prescribing an effective dose of Lovenox compared to standard doses recommended by the drug company in preventing blood clots from developing in the legs and lungs, and

• to compare the development of blood clots in patients receiving the standard dose of enoxaparin compared to patients receiving a TEG® guided dose of enoxaparin.

• to determine if TEG guided dosing results in decreased bleeding complications compared to standard dosing.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oregon Health and Science University
• Collaborators: Medical Research Foundation, Oregon; National Trauma Institute; National Trauma Research Institute
• Treatments: Enoxaparin; Enoxaparin sodium

Criteria

Inclusion Criteria:

• Inpatient initiated on enoxaparin thromboprophylaxis

• Age greater than 15 years

Exclusion Criteria:

• Unable to obtain consent from patient or ARR

• Presence of: intracranial hemorrhage, brain injury

• Receiving therapeutic dose enoxaparin

• Receiving other forms of anticoagulation

• Receiving non-standard dosing regimen of enoxaparin